Healthcare Equities

The companies that provide, support or coordinate medical goods and services. This sector spans a broad range of activities – including the development and manufacture of medical equipment, pharmaceuticals and other treatments. Activities range from research to manufacturing, administration, insurance and facilities management. Our Healthcare research includes healthcare services, healthcare information technology (IT), medical devices, biotechnology, biopharmaceuticals and specialty pharmaceuticals.

OpGen (OPGN)

Latest price

USD0.41

▾ −0.03 (−6.82)

As at 30/11/2023

Market capitalisation: USD4m

View equity

Update

Healthcare

14.08.23

OpGen — Cash concerns dampen active Q2

Flash note

Healthcare

04.08.23

OpGen — FIND collaboration advances to development

Flash note

Healthcare

21.07.23

EUR2.09

▾ 0.02 (0.97)

As at 30/11/2023

Market capitalisation: EUR122m

View equity

Flash note

Healthcare

27.11.23

Oryzon Genomics — Key €45m funding to back strategic priorities

Update

Healthcare

06.11.23

Oryzon Genomics — Q323 recap ahead of key clinical stages

Flash note

Healthcare

11.10.23

EUR3.93

▾ −0.02 (−0.51)

As at 30/11/2023

Market capitalisation: EUR86m

View equity

Flash note

Healthcare

27.11.23

OSE Immunotherapeutics — Collaboration bolsters upcoming Tedopi Phase III

edison tv

Healthcare

17.10.23

OSE Immunotherapeutics – executive interview with Nicolas Poirier, CEO

Flash note

Healthcare

17.10.23

GBP0.01

— 0.00 (0.00)

As at 30/11/2023

Market capitalisation: GBP7m

View equity

edison tv

Healthcare

31.10.23

Oxford Cannabinoid Technologies – executive interview

Flash note

Healthcare

12.10.23

Oxford Cannabinoid Technologies — Poised to progress to Phase II pending raise

Update

Healthcare

12.09.23

AUD0.39

▾ −0.01 (−1.27)

As at 30/11/2023

Market capitalisation: AUD139m

View equity

Update

Healthcare

02.11.23

Paradigm Biopharmaceuticals — Q1 results recap iPPS progress in OA & MPS

Flash note

Healthcare

25.10.23

Paradigm Biopharma — Disease modifying properties in iPPS Phase II

Update

Healthcare

17.10.23

EUR0.10

▾ 0.03 (42.86)

As at 30/11/2023

Market capitalisation: EUR1m

View equity

Flash note

Healthcare

25.09.23

Pharnext — Potential licensing deals could add confidence

Update

Healthcare

22.05.23

EUR0.15

▾ −0.04 (−21.05)

As at 30/11/2023

Market capitalisation: EUR1m

View equity

Flash note

Healthcare

10.10.23

Pixium Vision — Safeguard proceedings underway

Update

Healthcare

11.08.23

Pixium Vision — Shareholder loan extends runway

Update

Healthcare

02.05.23

AUD0.43

▾ −0.02 (−4.44)

As at 30/11/2023

Market capitalisation: AUD92m

View equity

Team of Research Scientists Working On Computer, with Medical Equipment, Analyzing Blood and Genetic Material Samples with Special Machines in the Modern Laboratory.

Update

Healthcare

23.08.23

Recce Pharmaceuticals — R327 progressing in rapid infusion study

Update

Healthcare

11.07.23

Recce Pharmaceuticals — Gearing up for more R327 studies

Initiation

Healthcare

08.03.23

—

— 0.00 (0.00)

As at 30/11/2023

Market capitalisation: —

View equity

thematic

01.04.22

Feeding the world

edison tv

Healthcare

09.02.22

Renaissance BioScience: Edison Open House Healthcare 2022

QuickView

Healthcare

21.01.22

GBP0.04

— 0.00 (0.00)

As at 30/11/2023

Market capitalisation: GBP2m

View equity

Update

Healthcare

27.11.23

ReNeuron Group — H124 results reaffirm focus on CustomEX

Flash note

Healthcare

15.09.23

ReNeuron Group — A step forward on the Exosome delivery platform

Update

Healthcare

30.05.23

AUD0.03

— 0.00 (0.00)

As at 30/11/2023

Market capitalisation: AUD31m

View equity

Update

Healthcare

12.09.23

Respiri — Access platform-led growth prospects ahead

Happy children launch a kite in the field at sunset. Little boy and girl on summer vacation

Flash note

Healthcare

30.08.23

Respiri — Early onset of synergies from Access acquisition

Flash note

Healthcare

14.08.23

GBP0.63

▾ 2.50 (4.17)

As at 30/11/2023

Market capitalisation: GBP44m

View equity

Update

Healthcare

12.10.23

Sareum Holdings — SDC-1801 embarks on clinical journey in FY23

Flash note

Healthcare

18.08.23

Sareum Holdings — £5m funding to see SDC-1801 through Phase I

Flash note

Healthcare

07.06.23

EUR2.65

— 0.00 (0.00)

As at 30/11/2023

Market capitalisation: EUR75m

View equity

Close up of Doctor is showing medical analytics data of Coronavirus (Covid-19), Medical technology concept

Update

Healthcare

13.11.23

Sequana Medical — MOJAVE early efficacy validates DSR 2.0

Update

Healthcare

25.09.23

Sequana Medical — On track to meet key milestones

Flash note

Healthcare

12.07.23

GBP0.06

— 0.00 (0.00)

As at 30/11/2023

Market capitalisation: GBP47m

View equity

Update

Healthcare

29.09.23

Shield Therapeutics — Ramped up and heading into a stronger H223

Update

Healthcare

04.05.23

Shield Therapeutics — FY23 a key year for business traction

Flash note

Healthcare

10.02.23

USD5.43

▾ 0.09 (1.69)

As at 30/11/2023

Market capitalisation: USD380m

View equity

Update

Healthcare

09.11.23

SIGA Technologies — International momentum building towards year-end

Flash note

Healthcare

24.10.23

SIGA Technologies — EU gateway to tap into new international orders

edison tv

Healthcare

09.10.23

NOK108.20

▾ −4.60 (−4.08)

As at 30/11/2023

Market capitalisation: NOK3,881m

View equity

Update

Healthcare

09.11.23

Ultimovacs — Staying alive with UV1 in NIPU and INTIUM

Flash note

Healthcare

02.11.23

Ultimovacs — Line of sight on INITIUM top-line readout

research

Healthcare

18.10.23

Ultimovacs — Overall survival is the name of the NIPU PII game

See more
content on

Ultimovacs

Equities

Equities by Sector

Sectors

Investment Strategy

Latest

Equity Strategy and Market outlook – October 2023

Equity strategy and market outlook – September 2023

Equity strategy and market outlook – August 2023

Thematics

Latest

Deutsches Eigenkapitalforum (EKF) 2023 consumer and media

Deutsches Eigenkapitalforum (EKF) 2023 technology

Deutsches Eigenkapitalforum (EKF) 2023 financials and investment companies

About Edison

About Edison

Careers

Healthcare Equities

OpGen (OPGN)

USD0.41

OpGen — Cash concerns dampen active Q2

OpGen — FIND collaboration advances to development

OpGen — Feasibility milestone from FIND collaboration

See morecontent on

Oryzon Genomics (ORY)

EUR2.09

Oryzon Genomics — Key €45m funding to back strategic priorities

Oryzon Genomics — Q323 recap ahead of key clinical stages

Oryzon Genomics — Favorable safety reported in PORTICO Phase II

See morecontent on

OSE Immunotherapeutics (OSE)

EUR3.93

OSE Immunotherapeutics — Collaboration bolsters upcoming Tedopi Phase III

OSE Immunotherapeutics – executive interview with Nicolas Poirier, CEO

OSE Immunotherapeutics — Anticipation builds with positive OSE-279 data

See morecontent on

Oxford Cannabinoid Technologies (OCTP)

GBP0.01

Oxford Cannabinoid Technologies – executive interview

Oxford Cannabinoid Technologies — Poised to progress to Phase II pending raise

Oxford Cannabinoid Technologies — Clinical headway rests on funding

See morecontent on

Paradigm Biopharma (PAR)

AUD0.39

Paradigm Biopharmaceuticals — Q1 results recap iPPS progress in OA & MPS

Paradigm Biopharma — Disease modifying properties in iPPS Phase II

Paradigm Biopharma — Durable responses observed for kOA

See morecontent on

Pharnext (ALPHA)

EUR0.10

Pharnext — Potential licensing deals could add confidence

Pharnext — Improving FY23 financial footing

Pharnext — Revised legal structure to offer operational stability

See morecontent on

Pixium Vision (PIX)

EUR0.15

Pixium Vision — Safeguard proceedings underway

Pixium Vision — Shareholder loan extends runway

Pixium Vision — Focusing on reaching the PRIMAvera milestone

See morecontent on

Recce Pharmaceuticals (RCE)

AUD0.43

Recce Pharmaceuticals — R327 progressing in rapid infusion study

Recce Pharmaceuticals — Gearing up for more R327 studies

Recce Pharmaceuticals — Seeking a breakthrough in sepsis

See morecontent on

Renaissance BioScience (RENABIOTICKER)

—

Feeding the world

Renaissance BioScience: Edison Open House Healthcare 2022

Renaissance BioScience — RNAi technology from bioengineered yeast

See morecontent on

ReNeuron Group (RENE)

GBP0.04

ReNeuron Group — H124 results reaffirm focus on CustomEX

ReNeuron Group — A step forward on the Exosome delivery platform

ReNeuron Group — Full steam ahead with CustomEx

See morecontent on

Respiri (RSH)

AUD0.03

Respiri — Access platform-led growth prospects ahead

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on